reports
- Robin Davison
Poolbeg ready to commence POLB 001 clinical study
Poolbeg Pharma is to commence a human challenge trial for its lead molecule POLB 001, a small molecule immunomodulator intended for the treatment of severe influenza, marking delivery against an important commitment made in its IPO a year ago. The company has received ethics and competent authority
- Robin Davison
Further expansion of AI-based R&D
Poolbeg Pharma yesterday announced a deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery programme aimed at identifying potential drug development candidates for the treatment of influenza. The move represents Poolbeg's second foray into AI-based
- Robin Davison
Poolbeg expands R&D portfolio
Poolbeg Pharma has in-licensed a late preclinical-stage, potentially broad-spectrum treatment for respiratory virus infections, representing the second expansion of its R&D pipeline in as many months. The new agent is a nasally-administered RNA-based approach with prophylactic and therapeutic a
- Robin Davison
Deal to acquire infectious disease vaccine candidates
Poolbeg has signed an option agreement with University College Dublin for MelioVac, a late preclinical-stage infectious disease vaccine for Burkholderia pseudomallei, the bacterium that causes the tropical disease melioidosis. The option provides a period of time for Poolbeg to complete its due dil
- Proactive Investors
Poolbeg Pharma: Trading now underway
Shares began trading on the 19th July 2021, in newly-listed Poolbeg Pharma after the company came to the market via an oversubscribed £25mln IPO. Poolbeg plans to develop a potential treatment for influenza and is aiming for a near-term partnership with big pharma. Poolbeg is a spin-out from Open O
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.